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Background: Defibrillation threshold (DFT) defined as the minimum amount of energy in joules required to defibrillate the heart is determined 
during implantation of Cardioverter-Defibrillator by DFT testing. Improvements in the field of defibrillator technology coupled with the possibility of 
numerous direct and indirect complications of DFT testing have led to questioning this conventional practice. Our aim was to perform a systematic 
literature review to analyze all studies that have evaluated the benefits and risks in DFT testing Vs no-DFT testing groups.
Methods and Results: A systematic literature search was performed on MEDLINE database for all existing articles using the search term 
“Defibrillation Threshold Testing”. The search yielded a total of 221 articles and a manual search for relevant articles yielded 2 more. Abstracts 
of all 223 articles were manually reviewed and 23 articles which met our pre-defined inclusion criteria were reviewed at length for the purpose 
of data abstraction. The studies were grouped together based on the outcomes studied like overall mortality, cardiovascular or neurological 
complications. While prospective studies concluded that long term mortality and clinical outcomes were not higher in the no-DFT testing group, 
retrospective studies showed otherwise. Meta-analysis with pooled estimate of overall mortality with DFT testing vs no-DFT testing revealed that 
the former was associated with higher overall mortality (109 vs 54). Also studies have consistently shown that DFT testing causes neuronal damage 
that is associated with long-term neuro-cognitive decline, and deterioration of myocardial performance in patients with preexisting left ventricular 
dysfunction.
Conclusion: DFT testing, apart from its inherent risk of neurological and cardiac complications, does not improve overall survival or predict clinical 
outcomes. More rigorous prospective studies and randomized control trials are required to demonstrate the futility of DFT testing. But the body of 
existing evidence is strong enough to steer away from this convention and perhaps device mathematical models to predict DFT based on clinical, 
physical and electrophysiological parameters.
